Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 20, 2021 01:00 ET | Source: ObsEva SA

ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix for the Treatment of Uterine Fibroids at ASRM 2021 Scientific Congress & Expo

-Final results from pilot study of linzagolix for the treatment of severe adenomyosis to be presented in a second poster - Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss...
October 19, 2021 01:00 ET | Source: ObsEva SA

ObsEva Announces Presentation of Clinical Data on Oral GnRH Antagonist Linzagolix at ASRM 2021 Scientific Congress & Expo

–Presentation of Phase 3 clinical data on linzagolix for the treatment of uterine fibroids and final results from a pilot study of linzagolix for the treatment of severe adenomyosis– GENEVA,...
October 18, 2021 09:12 ET | Source: Inherent Biosciences Inc

Inherent Biosciences Launches Path Fertility - Epigenetic Sperm Quality Test (SpermQT)

SALT LAKE CITY, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Inherent Biosciences, a molecular diagnostics company at the intersection of epigenetics and artificial intelligence (AI), today announced the...
October 22, 2020 01:00 ET | Source: ObsEva SA

ObsEva SA Presented Two Late-Breaking Posters at the ASRM 2020 Virtual Scientific Congress October 17-21

Geneva, Switzerland and Boston, MA – October 22, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s...
October 20, 2020 01:00 ET | Source: ObsEva SA

ObsEva SA Presented Nolasiban Poster at the ASRM 2020 Virtual Scientific Congress October 17-21

Geneva, Switzerland and Boston, MA – October 20, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s...
October 09, 2019 01:00 ET | Source: ObsEva SA

ObsEva SA to Present New Clinical Data on its Lead Compounds Nolasiban and Linzagolix at the 75th Annual ASRM Meeting in Philadelphia, PA

Geneva, Switzerland and Boston, MA –October 9, 2019- ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of...
October 09, 2018 16:15 ET | Source: ObsEva SA

ObsEva SA Presents Clinical Data from Phase III IMPLANT 2 Trial of Nolasiban in IVF at the American Society of Reproductive Medicine (ASRM) Annual Meeting

Abstract featuring-IMPLANT2 data awarded Prize Paper by Society for Assisted Reproductive Technology (SART) Nolasiban treatment shown to significantly increase Live Birth Rate (LBR) in...
October 05, 2018 01:00 ET | Source: ObsEva SA

ObsEva SA Announces Phase 3 IMPLANT 2 Clinical Trial Results of Nolasiban in IVF to be Presented at Annual ASRM Meeting Tuesday October 9, 2018

Recipient of Prize Paper Award from the Society for Assisted Reproductive Technology (SART) Geneva, Switzerland and Boston, MA - October 5, 2018- ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a...
October 02, 2017 09:30 ET | Source: Progyny

Progyny Expands its Clinical Leadership, adding Alan B. Copperman, M.D., FACOG as Medical Director

NEW YORK, Oct. 02, 2017 (GLOBE NEWSWIRE) -- Progyny, the leading fertility benefits company, today announced that Alan B. Copperman, M.D., FACOG has joined the Company as Medical Director. In his...